Overview

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
Phase:
Phase 2
Details
Lead Sponsor:
Eiger BioPharmaceuticals
Treatments:
Glucagon
Glucagon-Like Peptide 1